Published in BMC Infect Dis on December 01, 2015
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med (2000) 7.97
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep (2012) 6.91
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol (1999) 3.65
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med (2014) 3.50
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Natural history of hepatitis C. Hepatology (1997) 2.63
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis (2012) 2.15
Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis (2010) 1.96
Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis (1994) 1.78
HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care (2011) 1.51
Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis (1995) 1.41
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol (2012) 1.32
Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat (2010) 1.31
Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS (2010) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis (2012) 1.14
Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol (1996) 1.05
Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. Am J Public Health (2014) 0.94
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health (2012) 0.93
Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med (2014) 0.87
Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis. Arch Intern Med (1993) 0.86
Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health (2012) 0.84
French consensus conference on hepatitis C: screening and treatment. Gut (1998) 0.84
Characteristics of HCV positive patients in an Italian urban psychiatric unit. Clin Pract Epidemiol Ment Health (2006) 0.79